Frontpage Hero

Because we care, we need to act

Statement from the CEO

Building for balance and growth

"Sobi is delivering on a solid strategy for growth. Building on our strength in Haemophilia, we aim to grow the business with a broader Specialty Care portfolio to ensure long-term sustainability and strength and make a real difference for people with rare diseases."

Press releases

Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces its results for the fourth quarter and full-year 2017. Total revenues for the full-year amounted to SEK 6,511 M, an increase of 25 per cent. Revenues for the quarter were SEK 1,875 M, an increase of 45 per cent. Product sales for the full...

02/22/2018 - 08:00

On 22 February, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the fourth quarter and full year 2017.

Financial analysts and media are invited to participate in a telephone conference, which will include a presentation of the results, on the same day at 14:00...

02/13/2018 - 09:00

Swedish Orphan Biovitrum AB (publ) (Sobi™) will present new evidence at the upcoming 11th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), in Madrid, Spain, 7-9 February 2018. These data mark the company´s long-term commitment to elevate haemophilia...

02/07/2018 - 12:30

The Republic of Ireland has become the first country in Europe where every person with haemophilia will have access to the newest generation of haemophilia treatments, extended half-life therapies, under new supply contracts signed between the HSE (Health Services Executive) and Sobi.

A new...

02/07/2018 - 09:00
Contact us

Sobi Head Office

info@sobi.com
+46 8 697 20 00
Tomtebodavägen 23A
SE-112 76 Stockholm, Sweden